SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is experiencing significant attention amidst sharp volatility, primarily driven by recent analyst downgrades from major banks, which many in the community are interpreting as market manipulation. This has led to a split sentiment, with some lamenting price drops while others view it as a prime opportunity to "buy the dip" ahead of anticipated strong earnings and potential S&P 500 inclusion.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following its CES 2026 keynote, where CEO Lisa Su unveiled next-generation AI processors like the MI455 and MI500, projecting massive future AI adoption and detailing strategic partnerships. Despite these significant announcements and strong demand outlook, the stock has experienced a notable pullback, prompting community debate over "sell the news" dynamics and perceived market manipulation. Many investors see the current dip as a strategic long-term buying opportunity given the company's strong position in the AI and high-performance computing landscape.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant market momentum, primarily fueled by reports of persistent memory shortages and increasing demand for its storage solutions within the rapidly expanding AI infrastructure. This has created a highly polarized community discussion, with some investors celebrating its 'unstoppable' rise as a 'generational shift,' while others caution about an overextended 'bubble' and potential for sharp pullbacks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is actively trending following NVIDIA's unveiling of a new autonomous vehicle platform, which significantly intensifies competition in the self-driving sector. This development has sparked extensive community debate regarding Tesla's competitive lead in FSD and its high valuation, especially as reports circulate about softening sales in certain markets.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. (ALMS) is trending following the announcement of positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in treating moderate-to-severe plaque psoriasis, demonstrating strong efficacy and high skin clearance rates. This success is fueling community discussions about its potential as a highly competitive oral therapy, positioning the company for a future New Drug Application. While some anticipate continued upward momentum and potential for a short squeeze, others express caution regarding possible stock offerings and the competitive landscape.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is currently trending with strong community anticipation for a potential short squeeze, driven by its high short interest. Investors are keenly discussing the company's pivotal role in next-generation AI data centers, particularly its GaN and SiC power solutions aligning with NVIDIA's 800V AI factory architecture and recent strategic partnerships. This foundational technology is fueling optimism for a significant breakout in energy-efficient AI infrastructure.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is a major talking point amid accelerating AWS revenue, driven by AI infrastructure demand, and its expanded AI integrations like Alexa+. Market commentators are actively discussing its perceived undervaluation compared to peers and anticipating a significant re-rating as a compelling AI growth play.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is gaining significant attention following a U.S. Department of Energy (DOE) agreement for Project TETRA, which aims to accelerate the development of its Integral Molten Salt Reactor (IMSR) pilot plant. The community is buzzing about this as a potential "Oklo 2.0," highlighting its advanced nuclear technology as crucial for addressing the escalating energy demands from AI and industrial decarbonization. Despite prior volatility, many investors are viewing current price levels as key accumulation points in a rapidly expanding sector.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending strongly, driven by substantial ETF inflows and the recent rollout of new AI-powered market insight features. The community is buzzing with divided opinions, debating whether these developments signify sustained institutional adoption and utility for the asset or if current momentum will face profit-taking. This highlights the ongoing speculation surrounding XRP's long-term potential as a key bridge currency.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is actively discussed following its announcement to be an early adopter of NVIDIA's Vera Rubin NVL72 platform, reinforcing its position as a significant AI infrastructure provider. This comes amid recognition as a top stock for future growth by some analysts, driving conversations around its long-term potential. However, the community remains divided, with many expressing frustration over the stock's pronounced volatility and sharp intraday price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.

<ul class="summary-bullets"><li>FDA approval of Wegovy’s oral formulation gives Novo Nordisk an early lead in a potentially large new segment of the weight-loss market.</li><li>&nbsp;Pricing pressures, supply constraints, and intensifying competition from Lilly continue to be headwinds for the stock.</li><li>Sustained stock upside will depend on pill adoption, margin discipline, and the company’s ability to reaccelerate growth after a sharp reset.</li></ul>Novo Nordisk’s (NVO) year started on a sour note, as a broader stock uptrend seen since 2017 stalled and it began a steady descent, dragged by a host of factors. With the company likely to be the first to market with an oral diabetic pill following the U.S. FDA’s nod for the same, investors hope the stock may have hit bottom and is positioned to turn a new leaf in the new year.For the year-to-date period,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s stock</a> is down nearly 43%, while from its February peak, it is down a steeper 50%.&nbsp;That sets it on track for its worst year since 1984, according to Koyfin data.<img src="https://news.stocktwits-cdn.com/NVO_1_YEAR_Return_png_86f6e1f305.webp" alt="NVO 1 YEAR Return.png">Source: Koyfin<h2 class="st-heading-2">What Ailed NOVO Stock?</h2>Novo may have revolutionized the obesity drug race with its semaglutide diabetes drug, which was marketed as Ozempic. Initially, Ozempic was used off-label for weight loss before the Danish company gained regulatory approval for a higher dose of semaglutide, under the brand name Wegovy, exclusively for treating obesity.The weight-loss drug maker’s fortunes have since taken a turn for the worse. Citing lower growth for its GLP-1 treatment in diabetes and obesity, the company trimmed its 2025 forecast for the third time this year. To make matters worse, the company had to agree to a price cut for the direct-to-consumer sales in the U.S. to align with the Trump administration’s efforts to make drugs accessible and affordable.To make matters worse, late-stage trial results for NOVO’s next-generation drug CargiSema failed to resonate with investors, exerting further downward pressure on the stock.<h2 class="st-heading-2">Weight-Loss — Panacea For Stock?</h2>At least, the stock reaction to the FDA nod for the pill formulation of Wegovy suggests investors are optimistic about Novo Nordisk’s newest opportunity. The stock was up nearly 8% in the premarket session on Tuesday. If the premarket move holds in the regular session, the stock is on track for its best day in nearly a year. Lilly (LLY), which has taken a lead over Novo Nordisk in the obesity drug race, fell 0.71% in the premarket.Retail sentiment toward the stock has turned ‘extremely bullish’ following the release of the data, reversing from the ‘bearish’ mood seen a day ago.&nbsp;<figure class="image"><img style="aspect-ratio:716/442;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_23_at_7_18_06_AM_png_a08b931f72.webp" alt="Screenshot 2025-12-23 at 7.18.06 AM.png" width="716" height="442"></figure>A retail watcher&nbsp;<a href="https://stocktwits.com/Promisbarber/message/639949439">lauded</a> the approval as “great” but remained cautious. “But supply, pricing, and competition still matter,” they said. Another user&nbsp;<a href="https://stocktwits.com/showtime1/message/639949319">expects</a> the stock to go up by 30%.<h2 class="st-heading-2">The Road Ahead For Novo Nordisk</h2>According to McKinsey, nearly one in three adults in the U.S., or about 100 million people, meet the clinical criteria for obesity. Add to this the 900 million people worldwide, and the addressable opportunity swells. And a bulk of this target population will likely gravitate toward an oral pill.Citing analysts, a Reuters report <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-wins-us-approval-weight-loss-pill-2025-12-22/">said</a>, by 2030, pills may account for about 20% of the market, driven by demand from patients who prefer easier, non-invasive therapies. Christopher Chrisman, a managing director and partner at consultancy BCG, reportedly said:“The pills will not displace or replace the injections," said Christopher Chrisman, a managing director and partner at consultancy BCG, adding some patients may prefer to continue with weekly injections. But pills offer clear advantages to some people. There's travel convenience and no need for a fridge.”The 1.5-mg starting dose of the Wegovy pill will be available in early January. Reuters also said Novo and Lilly had agreed to offer starter doses of their weight‑loss pills at $149 per month for the U.S. government Medicare and Medicaid health insurance programs and to cash-paying customers via the White House's direct-to-consumer TrumpRx site.Novo Nordisk now has a lead over Lilly's oral pill to be sold under the brand name “Orforglipron,” a late-stage candidate. Lilly has filed for regulatory approval of the obesity pill.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/quantum-trade-heating-up-retail-thinks-2026-could-be-real-payoff/cLepm6CREuF">The Quantum Trade Is Heating Up Again — And Retail Thinks 2026 Could Be The Real Payoff</a>

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill

NVO has suffered a steep year-to-date decline amid slowing GLP-1 growth, pricing pressure, and investor disappointment over its pipeline, but year-end has brought some good news for the company.

Equity

NVO has suffered a steep year-to-date decline amid slowing GLP-1 growth, pricing pressure, and investor disappointment over its pipeline, but year-end has brought some good news for the company.


<ul class="summary-bullets"><li>Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the U.S.</li><li>Lilly strengthens its leadership with a deep pipeline, while Novo faces slowing growth, price cuts, and disappointing CargiSema data.</li><li>New entrants—from Wave Life Sciences to Amgen, AstraZeneca, and Pfizer—intensify competition in an expanding market.</li></ul>The weight-loss category has emerged as pharma’s new sweet spot, propelling Eli Lilly (LLY) to become the first trillion-dollar&nbsp;healthcare company. The momentum hasn’t been limited to the giants—several smaller players have also surged on the back of their obesity drug pipelines. The scramble for dominance in weight-loss therapeutics now mirrors the AI arms race in tech, with companies pouring capital, talent, and research into a market too transformative to ignore.<a href="https://stocktwits.com/symbol/WVE">Wave Life Sciences Ltd.’s (WVE) shares</a> jumped nearly 150% on Monday after the small-cap biotech announced positive interim early-stage trial data for its obesity treatment candidate, codenamed “WVE-007.” Wall Street went gaga over the data, with the stock receiving a raft of generous price target raises and even a few upgrades.&nbsp;<h2 class="st-heading-2">Anti-Obesity Drug Market — Bulky Opportunity</h2>The weight-loss drug market is currently essentially a duopoly — one dominated by Danish pharma giant Novo Nordisk (NVO) and Lilly. But there are hordes of other large-cap pharma giants and small fries waiting in the wings. But is the field lucrative enough to justify the strong interest?Morgan Stanley in May raised its global weight-loss medication market estimate for 2035 to $150 billion, calling it the peak potential, up from $105 billion. If the forecast proves accurate, the market is expected to grow exponentially, from $15 billion in 2024. According to the firm’s analyst Terence Flynn, “We believe we are now at an inflection point for the broadening of obesity drugs’ use, which will extend beyond the U.S. to larger numbers of patients globally.”Coherent Market Insights puts the global market opportunity at $82.55 billion by 2032, growing at a compounded annual growth rate (CAGR) of 18% from $25.87 billion in 2025. Health information technology company IQVIA estimates the anti-obesity medication market to grow at a CAGR of 13-15% to $130 billion by 2034.<h4 class="st-heading-4" style="text-align:center;">Obesity Drug Market: Rapid Growth Through 2035</h4><img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_3_48_53_AM_png_f0daa98697.webp" alt="Screenshot 2025-12-09 at 3.48.53 AM.png">Source: IQVIAAccording to McKinsey, nearly one in three adults in the U.S., or about 100 million people, meet the clinical criteria for obesity. Add to this the 900 million people worldwide, and the addressable opportunity swells.Currently, the market is dominated (96%) by a class of drugs called glucagon-like peptide (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These are injectable drugs that mimic natural gut hormones (GLP-1 and GIP) to slow digestion, reduce appetite, and lower blood sugar. Dual-class agonists, such as Lilly’s Zepbound (chemically, tirzepatide), combine agonist activity to produce a better effect by working synergistically in the brain and gut.Some of the other modalities used by currently marketed drugs and those in development are:<ul><li>Lipase inhibitors (block fat-digesting enzymes in the gut)</li><li>Appetite suppressants (target specific genes/receptors for hunger)</li><li>Hormone/analog-based agents (slow gastric emptying)</li><li>Genetic/receptor-targeted therapies (used for rare forms of obesity; work by regulating via the central nervous system)</li></ul>Wave Sciences’s WVE-007 uses RNA interference (RNAi) to silence the INHBE gene, thereby reducing Activin E protein levels and promoting fat burning.<h2 class="st-heading-2">Lily Soars, Novo Lags</h2>Novo Nordisk may have revolutionized the obesity drug race with its semaglutide diabetes drug, which was marketed as Ozempic. Initially, Ozempic was used off-label for weight loss before the Danish company gained regulatory approval for a higher dose of semaglutide, under the brand name Wegovy, exclusively for treating obesity.The company has further beefed up the portfolio with Saxenda, an injectable formulation used in adults and some adolescents.Novo Nordisk has also filed for regulatory approval for an oral formulation of its obesity drug and a long-acting GLP-1 analogue intended as a once-weekly treatment for obesity. The company also has several other candidates in various stages of development, including its next-generation drug candidate CargiSema.&nbsp;The weight loss credentials of CargiSema, gleaned from two late-stage trial results, haven’t lived up to the hype, serving as a drag on the stock. The company has, however, maintained that it is on track to file a regulatory submission in the first quarter of 2026.Rival Lilly’s has an FDA-approved obesity treatment, Zepbound, and its diabetes drug Mounjaro is also used to treat obesity. The company’s obesity pipeline is brimming with activity, including:&nbsp;<ul><li>Once-daily, oral GLP-1 receptor agonist Orforglipron (Phase 3 development)</li><li>Triple-acting injectable incretin called Retatrutide (targeting GLP1+GIP and glucagon receptors)</li><li>Once-weekly injectable late-stage candidate Eloralinitide</li><li>Mid-stage Bimagrunab that came into its stable through its Versanis Bio buy (works by reducing fat mass even while preserving muscle mass)</li></ul>Novo Nordisk’s weight-loss drug’s charm has since then declined. Citing lower growth for its GLP-1 treatment in diabetes and obesity, the company trimmed its 2025 forecast for the third time this year. To make matters worse, the company had to agree to a price cut for the direct-to-consumer sales in the U.S. to align with the Trump administration’s efforts to make drugs accessible and affordable.The slowing sales of this money-spinning portfolio led to the ouster of Lars Fruergaard Jorgensen in May. The board explicitly stated that the exit was due to market challenges it faced and the resulting decline in the stock price since mid-2024.Here’s a look at how obesity portfolios of both companies have fared:<img src="https://news.stocktwits-cdn.com/How_Much_Revenue_Do_Novos_Obesity_Drugs_Generate_jpg_9b42c387d7.webp" alt="How_Much_Revenue_Do_Novos_Obesity_Drugs_Generate.jpg"><img src="https://news.stocktwits-cdn.com/How_Much_Revenue_Do_Novos_Obesity_Drugs_Generate_jpg_5e73990a2a.webp" alt="How_Much_Revenue_Do_Novos_Obesity_Drugs_Generate.jpg">Source: Fiscal.ai*Ozempic and Mounjaro sales may not be entirely attributable to the obesity indication since they are used off-label for the indication.On Monday, JPMorgan slashed its price target for Novo Nordisk by 30% but maintained an ‘Overweight’ rating, the Fly reported. Argus downgraded the stock to ‘Hold’ from ‘Buy,’ citing the loss of share in the GLP-1 drug market and the price cuts in the U.S. The firm also flagged potential generic competition in some international markets and the lukewarm results from ongoing trials of pipeline candidates.&nbsp;On the other hand, Eli Lilly stock received a price target hike from Guggenheim to $1163 from $1,036. The firm said the action followed the updation of its models for the two obesity drug rivals to reflect prescription trends, GLP-1 pricing updates, and announcements.&nbsp;The stock prices of <a href="https://stocktwits.com/symbol/LLY">Lily</a> and <a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> have captured the reversing fortunes of both companies.&nbsp;<img src="https://news.stocktwits-cdn.com/LLY_VS_NVO_Stock_png_8157958009.webp" alt="LLY VS NVO Stock.png">Source: Koyfin<h2 class="st-heading-2">Other Players Knocking On The Door</h2><ul><li>Amgen - MariTide (Phase 3)</li><li>Boehringer Ingelheim - Survodutide (Phase 3)</li><li>AstraZeneca - AZD-6235, AZD-5004 (Phase 2)</li><li>Arrowhead - ARO-ALK7 (Phase 2)</li><li>Regeneron - Trevogrumab (Phase 2)</li><li>Roche - RG-6640 (Phase 2)</li><li>Pfizer - PR-07976016 (Phase 2)</li><li>Viking - VK-2735 (Phase 2)</li></ul><h2 class="st-heading-2">The Future</h2>Drugmakers see the shift from injectables to oral formulations as the holy grail of obesity treatment. Lilly and Novo Nordisk both have an oral drug candidate in late-stage development. The latter could leave the worst behind and regain its lead if it can convince regulators of Cargisema's efficacy and safety.&nbsp;Morgan Stanley sees the supply, additional clinical benefits for other diseases, expanded payer coverage, pill formulation and more efficient delivery mechanisms as factors that can increase the uptake of the obesity drugs.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-s-and-p-500-futures-freeze-amid-fresh-trump-tariff-threats-fed-jitters/cLIr8v9REZ5">Nasdaq, S&amp;P 500 Futures Freeze As Fresh Trump Tariff Threats On Mexico, India Collide With Fed Jitters — Strategist Warns Santa Rally Looks Unlikely</a>

Woman using Semaglutide injection pen. - stock photo

The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In

The obesity-drug boom is reshaping pharma, with Lilly surging ahead, Novo stumbling, and a wave of emerging players racing to capture a massive, fast-growing global market.

Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in 

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.


NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

THNR
Amplify Weight Loss Drug & Treatment ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest THNR News

THNRAmplify Weight Loss Drug & Treatment ETF